TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05519449: Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Sponsor: Janux Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 272 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT05519449 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05519449 Rescue Dossier →